Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of IDH305 in advanced IDH1R132-mutant malignancies
NL-OMON43902Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of idh305 in glioma, cholangiocarcinoma (CCA), acute myeloid leukemia (AML) and 2 more, sponsored by Novartis. Primary endpoint: Dose-limiting toxicities during cycle 1. Started Jul 2015; status: active, not recruiting.
02
Drugs
idh305
03
Conditions
gliomacholangiocarcinoma (CCA)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)advanced nonhematological malignancy
Beyond the preview
Go deeper on NL-OMON43902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43902.